Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry

Autoimmunity Reviews

Volumn 15, Issue 12, 2016, Pages 1120-1124

  Rodríguez Pintó, Ignasi ^a   Moitinho, Marta ^a   Santacreu, Irene ^a   Shoenfeld, Yehuda ^b   Erkan, Doruk ^c   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b SHEBA MEDICAL CENTER   (Israel)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anticardiolipin; Antiphospholipid; Antiphospholipid antibodies; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; IMMUNOLOGY; REGISTER;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS COAGULATION INHIBITOR; REGISTRIES;

EID: 84995665659     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.09.010     Document Type: Review

References (22)

1. [1] Hughes, G.R., Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 287:6399 (1983), 1088–1089.
2. [2] Cervera, R., Piette, J.-C., Font, J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:4 (2002), 1019–1027.
3. [3] Asherson, R.A., The catastrophic antiphospholipid syndrome. J Rheumatol 19:4 (1992), 508–512.
4. [4] Cervera, R., Rodríguez-Pintó, I., Colafrancesco, S., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 13:7 (2014), 699–707.
5. [5] Cervera, R., CAPS Registry. Lupus 21:7 (2012), 755–757.
6. [6] Asherson, R., Cervera, R., de Groot, P.G., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:7 (2003), 530–534.
7. [7] Cervera, R., Bucciarelli, S., Plasín, M.A., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 32:3–4 (2009), 240–245.
8. [8] Asherson, R.A., Cervera, R., Piette, J.C., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:3 (1998), 195–207.
9. [9] Asherson, R.A., Cervera, R., Piette, J.C., et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:6 (2001), 355–377.
10. [10] Garcia-Carrasco, M., Mendoza-Pinto, C., Macias-Diaz, S., et al. The role of infectious diseases in the catastrophic antiphospholipid syndrome. Autoimmun Rev 14:11 (2015), 1066–1071.
11. [11] Ortega-Hernandez, O.-D., Agmon-Levin, N., Blank, M., Asherson, R.A., Shoenfeld, Y., The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 32:1 (2009), 1–6.
12. [12] Espinosa, G., Cervera, R., Asherson, R.A., Catastrophic antiphospholipid syndrome and sepsis. A common link?. J Rheumatol 34:5 (2007), 923–926.
13. [13] Asherson, R.A., Shoenfeld, Y., The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome-molecular mimicry?. J Rheumatol 27:1 (2000), 12–14.
14. [14] Edgren, G., Liang, L., Adami, H.-O.O., Chang, E.T., Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 27:3 (2012), 187–196.
15. [15] Ramos-Casals, M., García-Carrasco, M., Brito, M.P., López-Soto, A., Font, J., Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 12:5 (2003), 341–355.
16. [16] Montoya-Ortiz, G., Immunosenescence, aging, and systemic lupus erythematous. Autoimmune Dis, 2013, 2013.
17. [17] Cervera, R., Khamashta, M.A., Font, J., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:2 (1993), 113–124.
18. [18] Cervera, R., Khamashta, M.A., Font, J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:5 (2003), 299–308.
19. [19] Ershler, W.B., Cancer: a disease of the elderly. J Support Oncol 1:4 Suppl. 2 (2003), 5–10.
20. [20] Denas, G., Jose, S.P., Bracco, A., Zoppellaro, G., Pengo, V., Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 14:3 (2015), 214–222.
21. [21] Bayraktar, U.D., Erkan, D., Bucciarelli, S., Espinosa, G., Asherson, R., The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 34:2 (2007), 346–352.
22. [22] Abreu, M.M., Danowski, A., Wahl, D.G., et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 14:5 (2015), 401–414.